Abstract: Provided is a site-specific PEG-modified interleukin 2 (IL-2) mutant. Compared with a parent IL-2, the mutant has an improved preference for a Treg cell and a prolonged half-life period. Also provided are a composition comprising the IL-2 mutant, a nucleic acid encoding the IL-2 mutant, a vector comprising the nucleic acid, and a host cell. Further provided are the IL-2 mutant and therapeutic use of a pharmaceutical composition comprising same.

Abstract: A volume adjustment method, a device and a storage medium are provided. The method includes: determining a reference volume corresponding to a target audio to be played; inputting target audio characteristic information corresponding to the target audio, target user group characteristic information provided by a target user group, current scenario characteristic information and the reference volume to an adjustment information prediction model that is pre-trained, to predict volume adjustment information and obtain target volume adjustment information; determining a target volume corresponding to the target audio according to the target volume adjustment information and the reference volume; and performing volume adjustment on the target audio based on the target volume, to enable an adjusted target audio to be played at the target volume.